6 Dimensions Capital

6 Dimensions Capital is a global healthcare investment firm that describes itself as investing in the next wave of global growth opportunities and cutting-edge innovation in the life sciences. According to its official website, the firm maintains offices in Boston, San Francisco, Hong Kong and Shanghai, giving it a cross-border presence spanning the United States and Greater China. It focuses on healthcare startups and growth-stage companies with operations in the U.S., Europe, China, Israel and other countries, and positions itself as helping entrepreneurs create and grow innovative healthcare businesses for the benefit of patients worldwide. The firm's stated approach combines disciplined investing with proactive partnering and active value creation through effective resource mobilization. Its investment scope covers the life sciences broadly, and its portfolio activity has included biopharmaceutical companies such as Curon Biopharmaceutical, Lyvgen Biopharma and Centrexion Therapeutics. In December 2017 the firm announced the closing of an oversubscribed first USD fund and RMB fund, bringing total assets under management to over RMB 10 billion (approximately USD 1.5 billion). 6 Dimensions Capital operates as a private investment organization rather than a listed company. Its dual-currency fundraising and its offices in both the United States and China reflect a strategy of bridging healthcare innovation and capital between the two markets. The firm has also been associated with incubation efforts, including Curon Biopharmaceutical, which completed a USD 150 million first round of financing in July 2018. Its Shanghai office relocated to Block 17, No. 999 Huanke Road, Pudong New District, effective May 1, 2018.

6 Dimensions Capital is a healthcare-focused investment firm that has built a cross-border platform spanning the United States and China. Its official website describes it as a leading global healthcare investment firm with offices in Boston, San Francisco, Hong Kong and Shanghai. The firm invests in healthcare startups and growth-stage companies with operations in the U.S., Europe, China, Israel and other countries, aiming to help entrepreneurs create and grow innovative healthcare businesses for patients worldwide. A significant milestone came in December 2017, when 6 Dimensions Capital announced the closing of an oversubscribed first USD fund and RMB fund, bringing total assets under management to over RMB 10 billion (approximately USD 1.5 billion). This dual-currency fundraising underscored the firm's strategy of operating across both U.S. dollar and Chinese renminbi capital markets. In 2018 the firm continued to expand and invest. On April 28, 2018, it announced that its Shanghai office would relocate to Block 17, No. 999 Huanke Road, Pudong New District, effective May 1, 2018. In July 2018, Lyvgen Biopharma completed a USD 30 million Series B funding round led by 6 Dimensions Capital, and Curon Biopharmaceutical, incubated by 6 Dimensions Capital, completed a USD 150 million first round of financing. The firm's portfolio also included Centrexion Therapeutics, which in March 2018 announced the first patient dosed in a Phase 3 trial of CNTX-4975 for moderate to severe knee osteoarthritis pain. 6 Dimensions Capital presents itself as pursuing disciplined investing and proactive partnering, with active value creation through effective resource mobilization. Its cross-border footprint and life sciences focus position it as a bridge between healthcare innovation and capital in the U.S. and Greater China.

• Closed oversubscribed first USD fund and RMB fund, bringing total AUM over RMB 10Bn (USD 1.5Bn)

• Announced Shanghai office relocation to Block 17, No.999 Huanke Road, Pudong New District, effective May 1, 2018

• Led USD 30 million Series B funding round in Lyvgen Biopharma

• Incubated company Curon Biopharmaceutical completed USD 150 million first round of financing

Leading global healthcare investment firm bridging U.S. and China life sciences innovation.

• USD fund

  First USD fund closed in December 2017 as part of oversubscribed fundraising.

• RMB fund

  First RMB fund closed in December 2017 alongside the USD fund.

1. 16 Dimensions Capital official website6dimensionscapital.com
2. 26 Dimensions Capital About Us6dimensionscapital.com
3. 3Wikidata: 6 Dimensions Capital (United States)wikidata.org